home / stock / cgtx / cgtx news

CGTX News and Press, Cognition Therapeutics Inc. From 01/10/22

Stock Information
Company Name: Cognition Therapeutics Inc.
Stock Symbol: CGTX
Market: NASDAQ
Website: cogrx.com
Menu
CGTX CGTX Quote CGTX Short CGTX News CGTX Articles CGTX Message Board
Get CGTX Alerts

News, Short Squeeze, Breakout and More Instantly...
CGTX - Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...
CGTX - Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson's Disease

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that the company has been awarded a...

CGTX - Cognition Therapeutics to Participate in Next-Generation Alzheimer's Disease Panel at Virtual Biotech Showcase on January 11, 2022

PURCHASE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders...

CGTX - Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...
CGTX - Cognition Therapeutics reports Q3 results

Cognition Therapeutics (NASDAQ:CGTX): Q3 GAAP EPS of -$8.12. Cash and cash equivalents of $8.3M Press Release For further details see: Cognition Therapeutics reports Q3 results

CGTX - Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

PURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...

CGTX - Cognition Therapeutics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in connection with Initial Public Offering

PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the cent...
CGTX - Catalyst watch for next week: FOMC and OPEC meetings, Beyond Meat hits McDonald's stores and more eyes on crypto

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Previous 10 Next 10